Moneycontrol PRO
you are here: HomeNewsMerck
merck
Jump to
121 Results Found
  • COVID-19: Is the hype around the oral drug Molnupiravir justified? Nov 10, 2021 05:08 PM IST

    COVID-19: Is the hype around the oral drug Molnupiravir justified?

    Molnupiravir increases our armamentarium against COVID-19, but it cannot replace vaccines. So, then what’s the hype all about? 

  • Explained | Pfizer v/s Merck: New anti COVID pill and its comparison Nov 08, 2021 07:16 PM IST

    Explained | Pfizer v/s Merck: New anti COVID pill and its comparison

    While Merck was the first to roll out its anti-COVID therapy, called molnupiravir, Pfizer has announced promising results of its own pill, called Paxlovid.

  • New COVID-19 pill cut hospital, death risk by 90%, says Pfizer Nov 05, 2021 04:58 PM IST

    New COVID-19 pill cut hospital, death risk by 90%, says Pfizer

    Currently all COVID-19 treatments used in the US require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.

  • EU medicines agency starts review of Merck oral COVID drug Oct 25, 2021 05:18 PM IST

    EU medicines agency starts review of Merck oral COVID drug

    The move, which could eventually lead to authorisation on the European market, comes two weeks after Merck applied for emergency use in the US of the anti-coronavirus drug.

  • Merck asks US regulators to authorize promising anti-COVID pill Oct 11, 2021 03:49 PM IST

    Merck asks US regulators to authorize promising anti-COVID pill

    Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.

  • Merck’s COVID-19 drug can be a game-changer Oct 06, 2021 08:49 AM IST

    Merck’s COVID-19 drug can be a game-changer

    Merck already has arrangements with eight Indian pharma companies to manufacture the drug and undoubtedly, all efforts will be made to make it more affordable than currently indicated

  • Merck spends $11.5 billion for Acceleron, possible blockbuster drug Sep 30, 2021 07:34 PM IST

    Merck spends $11.5 billion for Acceleron, possible blockbuster drug

    Merck executives told analysts Thursday they hope to launch the drug in either 2024 or 2025, and it has multi-billion dollar peak sales potential.

  • Coronavirus pandemic | Cipla to expand portfolio for COVID-19 drugs over next two months, says CFO May 17, 2021 02:29 PM IST

    Coronavirus pandemic | Cipla to expand portfolio for COVID-19 drugs over next two months, says CFO

    Swiss company Regeneron has signed with Cipla for exclusive distribution of its imported antibody cocktail in India.

  • Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term May 14, 2021 06:07 PM IST

    Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term

    Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold

  • Lupin: Focus on inhalation and bio-similars to aid margins in medium term May 14, 2021 11:03 AM IST

    Lupin: Focus on inhalation and bio-similars to aid margins in medium term

    In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets

  • Merck says study shows COVID-19 drug causes quick reduction in virus Mar 06, 2021 01:25 PM IST

    Merck says study shows COVID-19 drug causes quick reduction in virus

    "The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.

  • Merck to help produce J&J's COVID-19 vaccine Mar 02, 2021 07:14 PM IST

    Merck to help produce J&J's COVID-19 vaccine

    The announcement comes as the White House looks to speed the production of the single-dose vaccine.

  • Coronavirus Vaccine | How Merck, a vaccine titan, lost the COVID race Feb 11, 2021 01:30 PM IST

    Coronavirus Vaccine | How Merck, a vaccine titan, lost the COVID race

    Merck is now considering a range of options, both in the United States and around the world, mindful that anything it chooses to do would take months to bring to fruition, given the complexity of the manufacturing process

  • Merck CEO Kenneth Frazier to retire on June 30; CFO Robert Davis to be new chief Feb 04, 2021 08:13 PM IST

    Merck CEO Kenneth Frazier to retire on June 30; CFO Robert Davis to be new chief

    Frazier will continue to serve as executive chairman for Merck’s board of directors 'for a transition period to be determined by the board'.

  • US giant Merck stops development of two COVID-19 vaccine candidates Jan 25, 2021 06:57 PM IST

    US giant Merck stops development of two COVID-19 vaccine candidates

    Both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other COVID-19 vaccines, said Merck

  • COVID-19 update | Drugmaker Merck divests stake in vaccine-maker Moderna Dec 02, 2020 09:26 PM IST

    COVID-19 update | Drugmaker Merck divests stake in vaccine-maker Moderna

    Moderna is one of the front-runners in the race to develop a coronavirus vaccine, and on Monday filed for U.S. emergency use authorization of its vaccine.

  • Merck CEO Kenneth Frazier sees human trials for COVID-19 vaccine candidate 'fairly soon' Sep 03, 2020 09:59 PM IST

    Merck CEO Kenneth Frazier sees human trials for COVID-19 vaccine candidate 'fairly soon'

    Merck this year bought Austrian vaccine maker Themis Bioscience to gain its vaccine project that relies on a measles vector, and is also collaborating with research nonprofit IAVI on a second vaccine hopeful that uses the same technology as Merck’s Ebola vaccine ERVEBO.

  • Merck to buy Austrian vaccine maker as it jumps into COVID-19 race May 27, 2020 09:50 AM IST

    Merck to buy Austrian vaccine maker as it jumps into COVID-19 race

    It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19

  • AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer Dec 30, 2019 05:00 PM IST

    AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

    The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.

  • Ideas for Profit | A play on two promising markets – APIs and crop protection chemicals Jul 04, 2019 11:50 AM IST

    Ideas for Profit | A play on two promising markets – APIs and crop protection chemicals

  • Merck Standalone March 2019 Net Sales at Rs 231.03 crore, down 23.29% Y-o-Y May 13, 2019 10:33 AM IST

    Merck Standalone March 2019 Net Sales at Rs 231.03 crore, down 23.29% Y-o-Y

  • Comment | Merck’s dividend gift is extra special for P&G Feb 28, 2019 05:29 PM IST

    Comment | Merck’s dividend gift is extra special for P&G

    Merck’s Rs440 a share special dividend is good news for investors but more so for its new parent P&G. After the dividend, life for investors will return to mundane things such as performance-driven valuations

  • Merck Q3 net profit surges 65% to Rs 52.33 cr Oct 30, 2018 07:12 PM IST

    Merck Q3 net profit surges 65% to Rs 52.33 cr

    The company had posted a net profit of Rs 31.68 crore for the corresponding period previous fiscal, Merck Ltd said in a BSE filing.

  • P&G proposal for stake acquisition gets govt nod: Merck Oct 10, 2018 10:28 PM IST

    P&G proposal for stake acquisition gets govt nod: Merck

    The Department of Pharmaceuticals has approved the proposal of Procter & Gamble Overseas India BV for acquisition of up to 77.80 percent of the paid-up equity share capital of the company, Merck Ltd said in a filing to BSE.

  • Merck standalone Jun-2018 sales at Rs 220.29 crore Aug 08, 2018 12:00 PM IST

    Merck standalone Jun-2018 sales at Rs 220.29 crore

    Merck has reported a sales total income from operations of Rs 220.29 crore and a net profit of Rs 48.31 crore for the quarter ended Jun-2018

Sections
ISO 27001 - BSI Assurance Mark